FOCUS on muscle regeneration. A group at Wash. U. recently reported on a compound designated BE2012 in J. Med. Chem. BE2012 was shown to be a potent and selective antagonist at REV-ERBalpha and beta. In a mouse model of acute muscle injury, it promoted muscle regeneration and repair via upregulation of myogenic transcription factors. Thus REV-ERB may represent a promising new target for muscle regeneration and associated diseases.
